Editas Medicine (EDIT)

$3.80 -0.12 (-3.06%)
Market Cap 352.49M
Revenue (ttm) 32.31M
Net Income (ttm) -237.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -733.80%
Debt to Equity Ratio 0.00
Volume 2,518,500
Avg Vol 2,187,512
Day's Range N/A - N/A
Shares Out 89.92M
Stochastic %K 75%
Beta 2.18
Analysts Sell
Price Target $3.67

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 401 9000
Address:
11 Hurley Street, Cambridge, United States
0x126
0x126 Oct. 7 at 6:18 AM
$EDIT going down on low volume, need a cash flood in the sector or a single piece of good nows to go another 100%
0 · Reply
Fooligan
Fooligan Oct. 6 at 6:01 PM
$EDIT Rejected 4 again..picked up some calls today to go with my shares but looking kinda iffy with the underperformance...
0 · Reply
nrp
nrp Oct. 6 at 5:45 PM
$EDIT So many other opportunities, Why am i or are we in this POS.
0 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 6 at 5:39 PM
$EDIT not keeping up with the G stocks today.
0 · Reply
kfcthatsfried
kfcthatsfried Oct. 6 at 4:06 PM
$EDIT I WANNAAA SEEE REDDD BABYYY GIMME THAT ENTRY POINTTT
0 · Reply
Cytomight
Cytomight Oct. 6 at 3:14 PM
$EDIT Edit belongs at $13
1 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 6 at 2:34 PM
$EDIT they were selling at 3 then at 3.50 now 4. Skmbgs.
1 · Reply
harryvanluik
harryvanluik Oct. 6 at 1:54 PM
$EDIT Let's move through the 4,06 wall to see this stock gapping up hugely.
0 · Reply
Auto_MA_T_Ka
Auto_MA_T_Ka Oct. 5 at 10:37 PM
Editas Medicine $EDIT finds weekly MA support since April-May. -- 📉Find the BEST Respected Moving Average Support & Resistance Lines📈
0 · Reply
David_M_
David_M_ Oct. 5 at 3:33 PM
$EDIT
0 · Reply
Latest News on EDIT
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Oct 6, 2025, 9:00 AM EDT - 19 hours ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 11:14 AM EDT - 4 weeks ago

Editas Medicine, Inc. - Special Call

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Sep 2, 2025, 7:00 AM EDT - 4 weeks ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 5 weeks ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 5 weeks ago

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 7 weeks ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Jun 12, 2025, 2:01 AM EDT - 4 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 4 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 2:17 PM EDT - 5 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 9:31 AM EDT - 5 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 14, 2025, 7:01 AM EDT - 5 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 5 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:30 PM EDT - 5 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 12, 2025, 4:01 PM EDT - 5 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

May 5, 2025, 4:01 PM EDT - 5 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2025, 4:31 PM EDT - 5 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Announces Chief Financial Officer Transition

Mar 20, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine Announces Chief Financial Officer Transition

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 11, 2025, 4:07 PM EDT - 7 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 7 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 5, 2025, 4:05 PM EST - 7 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Mar 3, 2025, 5:01 PM EST - 7 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Feb 24, 2025, 9:00 AM EST - 8 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Jan 17, 2025, 12:20 PM EST - 9 months ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 15, 2025, 4:35 PM EST - 9 months ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 13, 2025, 9:00 AM EST - 9 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:00 AM EST - 9 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 13, 2024, 6:44 AM EST - 10 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 6:03 PM EST - 10 months ago

Editas to reduce about 65% of its workforce over the next six months

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 12, 2024, 4:00 PM EST - 10 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 10 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Dec 3, 2024, 10:52 PM EST - 10 months ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 25, 2024, 12:59 PM EST - 11 months ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 19, 2024, 7:53 PM EST - 11 months ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Editas Medicine: A Risk/Reward Worth Considering

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 12:03 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:01 AM EDT - 1 year ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

0x126
0x126 Oct. 7 at 6:18 AM
$EDIT going down on low volume, need a cash flood in the sector or a single piece of good nows to go another 100%
0 · Reply
Fooligan
Fooligan Oct. 6 at 6:01 PM
$EDIT Rejected 4 again..picked up some calls today to go with my shares but looking kinda iffy with the underperformance...
0 · Reply
nrp
nrp Oct. 6 at 5:45 PM
$EDIT So many other opportunities, Why am i or are we in this POS.
0 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 6 at 5:39 PM
$EDIT not keeping up with the G stocks today.
0 · Reply
kfcthatsfried
kfcthatsfried Oct. 6 at 4:06 PM
$EDIT I WANNAAA SEEE REDDD BABYYY GIMME THAT ENTRY POINTTT
0 · Reply
Cytomight
Cytomight Oct. 6 at 3:14 PM
$EDIT Edit belongs at $13
1 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 6 at 2:34 PM
$EDIT they were selling at 3 then at 3.50 now 4. Skmbgs.
1 · Reply
harryvanluik
harryvanluik Oct. 6 at 1:54 PM
$EDIT Let's move through the 4,06 wall to see this stock gapping up hugely.
0 · Reply
Auto_MA_T_Ka
Auto_MA_T_Ka Oct. 5 at 10:37 PM
Editas Medicine $EDIT finds weekly MA support since April-May. -- 📉Find the BEST Respected Moving Average Support & Resistance Lines📈
0 · Reply
David_M_
David_M_ Oct. 5 at 3:33 PM
$EDIT
0 · Reply
RocroBio
RocroBio Oct. 4 at 10:13 PM
$ABCL $CRBU $CRSP $EDIT
0 · Reply
RocroBio
RocroBio Oct. 4 at 10:12 PM
$EDIT $NTLA $PRME $VERV
0 · Reply
RocroBio
RocroBio Oct. 4 at 10:10 PM
$EDIT
1 · Reply
Thelonius_Stonk
Thelonius_Stonk Oct. 4 at 2:39 PM
$EDIT this thing workin
1 · Reply
3DBuilds
3DBuilds Oct. 4 at 10:29 AM
$CRBU $EDIT $NTLA $CRSP $PRME
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 7:29 AM
$EDIT: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $2.5 Exp on 02/20/2026 with Premium of $30K and showing BEARISH Sentiment
0 · Reply
harryvanluik
harryvanluik Oct. 4 at 7:22 AM
$EDIT Edit breaking out above the upper bollinger bands (1 year): very strong sign for a huge breakout. jmho https://finance.yahoo.com/chart/EDIT#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
0 · Reply
trendtrader6
trendtrader6 Oct. 3 at 11:05 PM
$ARKG weekly. genomics on the other hands seem to be just getting started $CRSP $EDIT
0 · Reply
0x126
0x126 Oct. 3 at 6:09 PM
$EDIT here it is. Sector dip before WE. Have a great one everyone
0 · Reply
0x126
0x126 Oct. 3 at 2:41 PM
$EDIT did expect a WE drop, not to open green! Wooo
0 · Reply
3DBuilds
3DBuilds Oct. 3 at 2:31 PM
$EDIT wooooo weeee 💯 💰
0 · Reply
Robert_Dempster
Robert_Dempster Oct. 3 at 1:32 PM
$EDIT been awhile since we touch four🐂📈
0 · Reply